Full Press Release Details
Intelligent Bio Solutions Inc. Announces Reverse
NEW YORK, December 12, 2025 - Intelligent
Bio Solutions Inc. (Nasdaq: INBS) ("Intelligent Bio Solutions" or the "Company"), a medical technology
company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-10 reverse split of
its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025. Trading of the Company's common
stock on The Nasdaq Capital Market ("Nasdaq") will continue, on a split-adjusted basis, with the opening of the markets on December
16, 2025, under the trading symbol "INBS" and new CUSIP number 36151G709.
The reverse stock split was approved by Intelligent
Bio Solutions' stockholders at the annual meeting of the Company's stockholders held on October 16, 2025, with the final ratio
to be determined by the Company's Board of Directors within the ratio range authorized by shareholders.
As a result of the reverse stock split, every 10 shares
of common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock. In
addition, proportionate adjustments will be made to outstanding equity-based awards and other equity rights, including warrants. No fractional
shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the
number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder
will be entitled to receive a cash payment in lieu of a fractional share. The par value of the common stock will remain unchanged at $0.01
per share after the reverse split, and the number of authorized shares of common stock will remain at 100 million shares. Immediately
after the reverse stock split becomes effective, the Company will have approximately 959,533 shares of common stock issued and outstanding.
The reverse split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's
equity, except to the extent the reverse split results in a stockholder receiving a cash payment in lieu of a fractional share, as described
About Intelligent Bio
Intelligent Bio Solutions
Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes
that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis,
which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens
for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection
in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The
Company's current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics
firms, mining, drug treatment organizations, and coroners.
For more information, visit:
Forward-Looking Statements:
Some of the statements in
this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.'s ability to successfully
develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure
regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements.
Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes,"
"estimates," "anticipates," "expects," "plans," "projects," "intends,"
"potential," "may," "could," "might," "will," "should," "approximately"
or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions'
public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as
of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Intelligent Bio Solutions Inc.
Pinto, Managing Director
Strategic Communications